



THE PRESCRIBER e-LETTER

Overview of More Restrictive Coverage Changes

Effective February 17, 2026

MassHealth evaluates the prior authorization (PA) status for drugs on an ongoing basis and updates the MassHealth Drug List accordingly. The list below outlines changes to the MassHealth Drug List that have been identified as more restrictive in nature. These updates take effect February 17, 2026.

Change in Prior Authorization Status

Effective February 17, 2026, the following gastrointestinal agent will require PA.

Linzess (linaclotide) – PA

Change in MassHealth Brand Name Preferred Over Generic Drug List Status

- a. Effective February 17, 2026, the following agents will be added to the MassHealth Brand Name Preferred Over Generic Drug List.
 - Lotronex (alosetron) – **PA**; BP, A90
 - Premarin (estrogens, conjugated); BP, A90
- b. Effective February 17, 2026, the following agents will be removed from the MassHealth Brand Name Preferred Over Generic Drug List.
 - Adderall XR (amphetamine salts extended-release)^{PD} – **PA < 3 years or ≥ 21 years and PA > 2 units/day**; #
 - Byetta (exenatide injection) – **PA**
 - Hetlioz (tasimelteon capsule) – **PA**; A90
 - Motegrity (prucalopride) – **PA**

Deletions

- a. The following drugs have been removed from the MassHealth Drug List because they have been discontinued by the manufacturer.
 - amphetamine extended-release 1.25 mg/mL oral suspension – **PA**
 - Bentyl (dicyclomine capsule, solution, 20 mg tablet); A90
 - Byetta (exenatide injection) – **PA**
 - Evekeo ODT (amphetamine sulfate orally disintegrating tablet) – **PA**
 - Synribo (omacetaxine mepesuccinate) – **PA**

The [MassHealth Drug List's Upcoming and Recent Updates](#) page summarizes changes that will become effective on February 17, 2026. Please refer to the updated summary for more information (including other important upcoming changes). Additional information about coverage status and PA requirements can be found on the [MassHealth Drug List website](#).

The Prescriber e-Letter is an update designed to enhance the transparency and efficiency of the MassHealth drug prior-authorization (PA) process and the MassHealth Drug List. Each issue highlights key clinical information and updates to the MassHealth Drug List. The Prescriber E-Letter was prepared by the MassHealth Drug Utilization Review Program and the MassHealth Pharmacy Program.

Please send any **suggestions** or **comments** to prescribereletter@massmail.state.ma.us